Mallinckrodt International Finance S A, headquartered in Luxembourg, was founded to provide financing solutions for its parent company, Mallinckrodt Pharmaceuticals, which focuses on specialty pharmaceuticals and biotechnology. The company primarily offers a range of financial services, including debt issuance, to support its operations and strategic initiatives.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| MNK 14.75% 2028-11-14 USDMallinckrodt International Finance S A | Luxembourg | 2028-11-14 | 14.750 | 13.66 |
| MNK 14.75% 2028-11-14 USDMallinckrodt International Finance S A | Luxembourg | 2028-11-14 | 14.750 | 13.77 |
| MNK 14.75% 2028-11-14 USDMallinckrodt International Finance S A | Luxembourg | 2028-11-14 | 14.750 | 13.66 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Mallinckrodt International Finance S A commenced bond issuances in 2014 with a notable $1.4 billion offering to refinance existing debt and fund corporate activities. Noteworthy bonds include a $400 million issuance with a 6.125% coupon rate, which has drawn attention for its competitive yield relative to industry averages. As of 2023, the company's bonds are trading favorably in the market, reflecting investor confidence despite challenges in the pharmaceutical sector.